Cancer BiologybioRxivPreprint
Radioligand therapy in combination with CAR T cells overcomes the heterogeneous immunosuppressive prostate tumor microenvironment
Jiangyue Liu, Iveta Fajnorovà, Yuwei Ren…·Saul J. Priceman
Combining 177Lu-PSMA-617 radioligand therapy with PSCA-CAR T cells improves tumor control and survival in prostate cancer models by overcoming antigen heterogeneity and reshaping the immunosuppressive tumor microenvironment.
DOI 10.64898/2026.07.02.736191